Literature DB >> 17825057

Divergent differentiation in malignant melanomas: a review.

S S Banerjee1, B Eyden.   

Abstract

The aim of this review was to document and discuss diagnostic problems associated with divergent differentiation ('metaplastic change') in malignant melanomas, defined as the development in these tumours of morphologically, immunohistochemically and/or ultrastructurally recognizable non-melanocytic cell or tissue components. Types of divergent differentiation reported in malignant melanoma include: fibroblastic/myofibroblastic, Schwannian and perineurial, smooth muscle, rhabdomyosarcomatous, osteocartilaginous, ganglionic and ganglioneuroblastic, neuroendocrine and probable epithelial. Divergent differentiation is certainly a rare phenomenon and, when it occurs, can be missed by unwary pathologists and lead to diagnostic uncertainty. A carefully chosen immunohistochemical panel and the input of electron microscopy can help to clarify the nature of the cellular differentiation of these tumours and lead to a correct final diagnosis. The clinical significance of such aberrations is uncertain, nor are the underlying mechanisms as yet well defined.

Entities:  

Mesh:

Year:  2007        PMID: 17825057     DOI: 10.1111/j.1365-2559.2007.02823.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  29 in total

1.  Zebrafish models of rhabdomyosarcoma.

Authors:  Eleanor Y Chen; David M Langenau
Journal:  Methods Cell Biol       Date:  2011       Impact factor: 1.441

2.  Metastatic melanoma with striking adenocarcinomatous differentiation illustrating phenotypic plasticity in melanoma.

Authors:  John R Jalas; Swapna Vemula; Vladimir Bezrookove; Philip E Leboit; Jeffry P Simko; Boris C Bastian
Journal:  Am J Surg Pathol       Date:  2011-09       Impact factor: 6.394

3.  Melanoma with rhabdomyosarcomatous differentiation.

Authors:  Aditya Kuwadekar; Justin Allard; Michael Dardik; Franz Smith
Journal:  BMJ Case Rep       Date:  2018-06-06

4.  Primary malignant tumour of the lung with neuroendocrine and melanoma differentiation.

Authors:  Emanuela Pilozzi; Claudio Cacchi; Arianna Di Napoli; Benedetto Pini; Enrico Duranti; Antonio D'Andrilli; Luigi Ruco
Journal:  Virchows Arch       Date:  2011-07-07       Impact factor: 4.064

Review 5.  Schwann cells: a new player in the tumor microenvironment.

Authors:  Yuri L Bunimovich; Anton A Keskinov; Galina V Shurin; Michael R Shurin
Journal:  Cancer Immunol Immunother       Date:  2016-11-24       Impact factor: 6.968

6.  Anti-CD10 (56C6) is expressed variably in adrenocortical tumors and cannot be used to discriminate clear cell renal cell carcinomas.

Authors:  Ozgür Mete; Yersu Kapran; Mine G Güllüoğlu; Işin Kiliçaslan; Yeşim Erbil; Yasemin Giles Senyürek; Ferhunde Dizdaroğlu
Journal:  Virchows Arch       Date:  2010-05       Impact factor: 4.064

Review 7.  Translational pathology, genomics and the development of systemic therapies for acral melanoma.

Authors:  Yian Ann Chen; Jamie K Teer; Zeynep Eroglu; Jheng-Yu Wu; John M Koomen; Florian A Karreth; Jane L Messina; Keiran S M Smalley
Journal:  Semin Cancer Biol       Date:  2019-11-02       Impact factor: 15.707

Review 8.  Malignant Melanoma: Autoimmunity and Supracellular Messaging as New Therapeutic Approaches.

Authors:  Ion G Motofei
Journal:  Curr Treat Options Oncol       Date:  2019-05-06

Review 9.  Rhabdomyoblastic Differentiation in Head and Neck Malignancies Other Than Rhabdomyosarcoma.

Authors:  Justin A Bishop; Lester D R Thompson; Antonio Cardesa; Leon Barnes; James S Lewis; Asterios Triantafyllou; Henrik Hellquist; Goran Stenman; Jennifer L Hunt; Michelle D Williams; Pieter J Slootweg; Kenneth O Devaney; Douglas R Gnepp; Bruce M Wenig; Alessandra Rinaldo; Alfio Ferlito
Journal:  Head Neck Pathol       Date:  2015-03-11

10.  Gene expression signature for spontaneous cancer regression in melanoma pigs.

Authors:  Florian Rambow; Guillaume Piton; Stephan Bouet; Jean-Jaques Leplat; Sylvain Baulande; Angelique Marrau; Mark Stam; Vratislav Horak; Silvia Vincent-Naulleau
Journal:  Neoplasia       Date:  2008-07       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.